High relapse rates after budesonide in microscopic colitis: a large retrospective analysis revealing the need for advanced therapies
Acta Gastro-Enterologica Belgica · 2026-06 · 89 (2) · 295-302
DOI: 10.51821/89.2.15176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Gastro-Enterologica Belgica, 2026-06. Verfasst von T Taelman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Budesonide, Colitis, Microscopic, Anti-Inflammatory Agents.
Abstract (Originalsprache)
Background
Microscopic colitis (MC) is a chronic inflammatory bowel disorder causing watery diarrhea despite normal endoscopic findings. Budesonide is the only approved therapy, yet long-term durability and the need for alternatives in steroid-dependent or -refractory cases remain unclear.
Methods
We performed a retrospective single-center cohort study of all patients with histologically confirmed MC between 2013 and 2022, with ≥3 months of follow-up. Demographics, clinical features, treatments, and outcomes were collected. Clinical remission followed Hjortswang criteria: fewer than three stools per day or fewer than one watery stool per day on average.
Results
A total of 239 idiopathic MC patients met inclusion criteria. Spontaneous remission occurred in 19.2%, more often in males (OR 2.39, p=0.02). Corticosteroids, predominantly budesonide, were prescribed in 78.7% and induced remission in 75.5% within three months. Relapse affected 54.8% of responders, typically during tapering (44.6%) or shortly after cessation (55.3%). Younger age predicted relapse (OR 0.97, p=0.003). Conventional alternatives, including 5-ASA, cholestyramine, methotrexate, and azathioprine, were largely ineffective after corticosteroid failure or dependency. Advanced therapies (anti-TNF agents, vedolizumab, JAK inhibitors) were initiated in 12.6%, more often in younger patients (OR 0.95, p=0.001) and those with a family history of IBD (OR 4.11, p=0.03). These therapies achieved post-induction remission in 70% of refractory cases. Two patients required colectomy.
Conclusion
In this large cohort with long-term follow-up, budesonide remained the primary treatment, yet over half of responders relapsed during tapering or after discontinuation. Conventional alternatives showed limited benefit. Advanced therapies demonstrated meaningful effectiveness in steroid-refractory or steroid-dependent MC, underscoring the need for broader therapeutic options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
- Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
Zitieren
APA
Taelman, T., Lenfant, M., Vermeire, S., Ferrante, M., Sabino, J., & Verstockt, B. (2026). High relapse rates after budesonide in microscopic colitis: a large retrospective analysis revealing the need for advanced therapies. Acta Gastro-Enterologica Belgica, 89(2), 295-302. https://doi.org/10.51821/89.2.15176
Vancouver
Taelman T, Lenfant M, Vermeire S, Ferrante M, Sabino J, Verstockt B. High relapse rates after budesonide in microscopic colitis: a large retrospective analysis revealing the need for advanced therapies. Acta Gastro-Enterologica Belgica. 2026;89(2):295-302. doi:10.51821/89.2.15176
BibTeX
@article{Taelman2026,
author = {Taelman, T and Lenfant, M and Vermeire, S and Ferrante, M and Sabino, J and Verstockt, B},
title = {High relapse rates after budesonide in microscopic colitis: a large retrospective analysis revealing the need for advanced therapies},
journal = {Acta Gastro-Enterologica Belgica},
year = {2026},
volume = {89},
number = {2},
pages = {295--302},
doi = {10.51821/89.2.15176}
}
EUVIMED